This grant application requests support the continued participation of the Memorial Sloan-Kettering Cancer Center and its affiliate hospitals in the research protocols of the Childrens Cancer Group. The clinical studies are designed to improve the survival of children with cancer through multidisciplinary randomized, collaborative treatment protocols that are stratified to the patients' stages of disease and their prognostic groups. Whenever possible the treatments are reduced to minimize both short and long-term toxicity. Epidemiologic studies are conducted to study the incidence, natural history and possible causes of childhood malignancies. Laboratory studies will be conducted to study the biology of cancer cells and correlate these with the clinical variables.
The aims of our participation and those of CCG are a) to provide large numbers of patients for groupwide studies in order to make multiarm, randomized, prospective studies possible, b) to utilize the scientific leadership, expertise and clinical experience of Pediatric Oncologists and other experts at MSKCC to help design and implement new studies, and c) to contribute scientific and administrative expertise and experience to Standing Committees of CCG. Clinical studies at MSKCC will continue in the evaluation and development of new chemotherapeutic agents for patients who become refractory to conventional therapy. Pharmacologic studies will evaluate drug metabolism and correlate it with therapeutic response. Studies will be conducted in the role of bone marrow transplantation in hematopoietic disorders and refractory solid tumors. The extensive clinical facilities of MSKCC with its well developed intensive supportive care program and its research laboratories will make it possible to develop novel treatment protocols. They will be piloted and made available for groupwide randomized prospective trials. The clinical personnel of MSKCC have extensive and proven experience in the design and implementation of innovative treatment protocols that have been adopted worldwide. They will continue to provide leadership for CCG in study committees and strategy groups. Current pilot studies at MSKCC that will become available for CCG use during this grant period include protocol for high-risk ALL, a retrieval protocol for refractory Hodgkin's disease, a new CNS leukemia therapy, a new osteogenic sarcoma protocol and a monoclonal antibody treatment for neuroblastoma. Members of the affiliate hospitals have been participating in CCG studies and have proven their ability to conduct the clinical studies and provide material for laboratory evaluation.
|Neudorf, Steven; Sanders, Jean; Kobrinsky, Nathan et al. (2004) Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 103:3655-61|
|Seitzman, Robin L; Glover, Dorie A; Meadows, Anna T et al. (2004) Self-concept in adult survivors of childhood acute lymphoblastic leukemia: a cooperative Children's Cancer Group and National Institutes of Health study. Pediatr Blood Cancer 42:230-40|
|Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8|
|Casillas, Jacqueline N; Woods, William G; Hunger, Stephen P et al. (2003) Prognostic implications of t(10;11) translocations in childhood acute myelogenous leukemia: a report from the Children's Cancer Group. J Pediatr Hematol Oncol 25:594-600|
|Davies, Stella M; Bhatia, Smita; Ross, Julie A et al. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100:67-71|
|Wells, Robert J; Reid, Joel M; Ames, Matthew M et al. (2002) Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatr Hematol Oncol 24:89-93|
|Lange, Beverly J; Bostrom, Bruce C; Cherlow, Joel M et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-33|
|Ou, Shu Xiao; Han, Dehui; Severson, Richard K et al. (2002) Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control 13:15-25|
|Cairo, M S; Krailo, M D; Morse, M et al. (2002) Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia 16:594-600|
|Wells, R J; Arthur, D C; Srivastava, A et al. (2002) Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 16:601-7|
Showing the most recent 10 out of 11 publications